3 completed, 1 recruiting. 2 Phase 4, 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Extended Treatment: new trials by email Literature Review of Extended Treatment trials Research Report on Extended Treatment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria omalizumab 300 mg every four weeks, omalizumab 300 mg every six weeks - Chronic Spontaneous Urticaria, Chronic Urticaria, Idiopathic | Phase 4 | Recruiting | Simon Francis Thomsen | 40 | 2024-01-12 | 2025-09-19 |
| Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment Combination Bupropion + NRTs, Extended Treatment, Home Visits & Calls - Smoking Cessation, Schizophrenia | Phase 4 | Completed | Brentwood Biomedical Research Institute | 42 | 2014-01-01 | 2019-07-30 |
| Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry Brief Intervention, Extended Treatment, Usual Care - Tobacco Dependence | Not applicable | Completed | Stanford University | 956 | 2009-09-01 | 2025-06-11 |
| Extended Cessation Treatment for Teen Smokers Extended treatment - Nicotine Dependence | Phase 2 / Phase 3 | Completed | Stanford University | 141 | 2006-09-01 | 2016-05-30 |
Smoking Cessation (2) · Tobacco Use Disorder (2) · Chronic Urticaria (1) · Schizophrenia (1)
Stanford University (2) · Brentwood Biomedical Research Institute (1) · Simon Francis Thomsen (1)
United States (3) · Denmark (1)
Joel D Killen, PhD (1) · Judith J. Prochaska, PhD, MPH (1)
PMID 23460656, PMID 24467257, PMID 25209524, PMID 25419703, PMID 39762098
R01CA118035 (1), R01MH083684 (1)